SCHEMBL4745872

SCHEMBL4745872

c1ccc2c(c1)-c1cccc3c(-c4cc5c6cccc7c6c(cc5c5ccccc45)-c4ncccc4-7)ccc-2c13

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTPRC P08575 2/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
PTPN13 Q12923 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746256 0.97 PTPRC (0.38) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4746255 0.97 PTPRC (0.38) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4746407 0.97 PTPRC (0.40) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL13320385 0.95 ALDH1A1 (0.44) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL13320396 0.95 ALDH1A1 (0.44) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4746392 0.95 ALDH1A1 (0.41) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4746454 0.94 ALDH1A1 (0.40) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4745978 0.94 ALDH1A1 (0.47) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4746267 0.94 ALDH1A1 (0.42) ALDH1A1HPGDTSHRMAPK1CASP1
SCHEMBL4745841 0.90 ALDH1A1 (0.44) ALDH1A1HPGDTSHRMAPK1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 ALDH1A1 179/4885HPGD 1775/4885TSHR 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.